This excerpt taken from the NTII 10-Q filed May 10, 2005.
We expect that we will need to raise additional capital to fund ongoing operations. If we are unable to raise additional capital, we may be forced to curtail operations. If we succeed in raising additional capital through a licensing or financing transaction, it may affect our stock price and future revenues.
In order to maintain sufficient cash and investments to fund future operations, we will need to raise additional capital. We are seeking to raise up to $25 million over the next 12 to 24 months through various
alternatives, including licensing or sales of our technologies and drug candidates and selling shares of our common stock.